Part

Benjamin Hill Mining Corp. Announces Private Placement of Units

Retrieved on: 
Monday, March 4, 2024
Acquisition, Regulation, Prospectus, Exemption, Part, Rule, CDN, Sale, Exercise, Indian stock exchange, National instrument, Share (finance), BNN, Agent, Offering, Accreditation, Security (finance)

Each Unit will consist of one common share in the capital of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”).

Key Points: 
  • Each Unit will consist of one common share in the capital of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”).
  • The securities offered under the Listed Issuer Financing Exemption will not be subject to a hold period in accordance with applicable Canadian securities laws.
  • The issuance of the Common Shares under the Shares for Debt Transaction is subject to acceptance for filing by the CSE.
  • All Common Shares to be issued in connection with the Shares for Debt Transaction will be subject to a four month and one day hold.

Molecular Templates, Inc. Provides Interim Update

Retrieved on: 
Monday, March 4, 2024
Therapy, Head, Neoplasm, Neck, CLS, AML, Part, TME, Sale, Pembrolizumab, Multiple myeloma, Bristol Myers Squibb, Symantec Endpoint Protection, TPS, Hyponatremia, Cytokine, Hypertension, Tumor microenvironment, Patient, Immunoglobulin A, MD Anderson Cancer Center, Hyperlipidemia, Disease, Biology, HNSCC, Hypercholesterolemia, CPS, PD-L1, Cancer, Pharmaceutical industry

Unique pharmacodynamic effects demonstrating potent Treg clearance and IL-2 increases were observed at the first dose level.

Key Points: 
  • Unique pharmacodynamic effects demonstrating potent Treg clearance and IL-2 increases were observed at the first dose level.
  • MTEM intends to initiate a study of MT-0169 in CD38+ acute leukemias in collaboration with MD Anderson Cancer Center.
  • Additional details on each of these participant’s clinical profile and response to the investigational treatment are provided below.
  • MTEM plans on initiating an investigator sponsored trial with MD Anderson Cancer Center to evaluate MT-0169 in relapsed or refractory CD38+ AML patients.

BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheime

Retrieved on: 
Friday, March 1, 2024
L-DOPA, MCP1, Chemokine, Alzheimer's disease, Phagocytosis, Political moderate, Principal, MDS-UPDRS, Cholesterol, Insulin, Inflammation, Part, ADAS, Plaque, Conference, Placebo-controlled study, Parkinson's disease, Diabetes, Carbidopa/levodopa, Pharmacokinetics, Digestion, Disease, DNA methylation, DNA, Brain, Pharmaceutical industry

CARSON CITY, Nev., March 01, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced two upcoming presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024 (AD/PD™ 2024) to be held March 5-9, 2024 in Lisbon, Portugal.

Key Points: 
  • These findings complement previously reported improvement in motor symptoms in patients treated with NE3107 and demonstrate potential intrinsic, levodopa-enhancing activity of NE3107 that is consistent with data from animal models.
  • NE3107-treated patients experienced a significant improvement of -2.4 points for the sleep/fatigue domain of the Non-Motor Symptom Scale (NMSS) in Parkinson’s Disease, whereas placebo patients experienced a worsening of +1.0 points (p=0.0159).
  • Sleep/fatigue domain improvements correlated with motor score improvements (r=0.51; p=0.0259).
  • More patients on NE3107 had improvements in the NMSS sleep/fatigue domain, while more patients on placebo worsened.

Navitas Semiconductor Announces Record Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, February 29, 2024
Internet, EV, Failure, Silicon, Zeekr, Research, Epidemic, Part, Growth, OPPO, Samsung, Original equipment manufacturer, BYD, Conference, Smart, GAAP, COVID-19, Silicon carbide, Part 1, Geely, Gallium nitride, Probability, Risk, Volvo, Hyundai, Video game

Gross Margin: GAAP gross margin for the fourth quarter of 2023 was 42.2%, compared to 40.6% in the fourth quarter of 2022 and 32.3% for the third quarter of 2023.

Key Points: 
  • Gross Margin: GAAP gross margin for the fourth quarter of 2023 was 42.2%, compared to 40.6% in the fourth quarter of 2022 and 32.3% for the third quarter of 2023.
  • Non-GAAP gross margin for the fourth quarter of 2023 was 42.2% compared to 40.6% for the fourth quarter of 2022 and 42.1% for the third quarter of 2023.
  • Loss from Operations: GAAP loss from operations for the quarter was $26.8 million, compared to a loss of $31.2 million for the fourth quarter of 2022 and a loss of $28.6 million for the third quarter of 2023.
  • On a non-GAAP basis, loss from operations for the quarter was $9.7 million compared to a loss of $12.4 million for the fourth quarter of 2022 and a loss of $8.7 million for the third quarter of 2023.

GXO Announces Offer to Acquire Wincanton

Retrieved on: 
Thursday, February 29, 2024
GXO, CEVA, CEVA Logistics, Part, Growth, Acquisition, RNS, NOT, Automation, LAWS, EPS, Wincanton plc, CMA

Under the terms of the offer, each Wincanton shareholder will be entitled to receive 605 pence in cash for each Wincanton share held.

Key Points: 
  • Under the terms of the offer, each Wincanton shareholder will be entitled to receive 605 pence in cash for each Wincanton share held.
  • GXO has received irrevocable undertakings to accept (or to procure the acceptance of) the offer in respect of, in aggregate, 42,395,691 Wincanton shares and representing approximately 34.0% of the issued share capital of Wincanton as at 29 February 2024.
  • The irrevocable undertakings will cease to be binding in certain situations, including where a third party announces a competing offer where the value of the consideration is more than 695 pence per Wincanton share.
  • Wincanton customers will have the opportunity to seamlessly globalize their supply chain operations across the 27 countries where GXO operates.

GENFIT Announces Revenues and Cash Position as of December 31, 2023

Retrieved on: 
Thursday, February 29, 2024
Marketing, EMA, New Drug Application, MAA, Annual report, FDA, Food, Part, PDUFA, NTZ, PBC, Primary biliary cholangitis, Collaboration, European Medicines Agency, Patient, Elafibranor, NDA, Research, Priority review, Pharmaceutical industry

As of December 31, 2023, the Company’s cash and cash equivalents amounted to €77.8 million compared with €140.2 million as of December 31, 2022.

Key Points: 
  • As of December 31, 2023, the Company’s cash and cash equivalents amounted to €77.8 million compared with €140.2 million as of December 31, 2022.
  • As of September 30, 2023, cash and cash equivalents totaled €93.9 million.
  • Revenues for 2023 amounted to €28.6 million compared to €20.2 million for the same period in 2022.
  • The 2023 Universal Registration Document, the 2023 Annual Financial Report (included in the 2023 Universal Registration Document), and the Annual Report on Form 20-F will be published by the end of April 2024.

Fobi AI Announces Completion of Fully Subscribed Upsized Non-Brokered LIFE Offering and & New Non-Brokered Placement

Retrieved on: 
Wednesday, February 28, 2024
TSX Venture Exchange, AI, Marketing, News, Part, Finder, Sale, Exercise, Warrant, PI, Indian stock exchange, National instrument, Acceleration, The Finders (movement), Security (finance)

VANCOUVER, BC, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Fobi AI Inc. (FOBI:TSXV) (FOBIF:OTCQB) (the "Company" or "Fobi"), an industry leader in harnessing AI and data intelligence to enable digital transformation, is pleased to announce that, further to its press releases dated February 2, 2024, February 23, 2024 and February 26, 2024, it has completed the final closing of its previously announced fully-subscribed upsized non-brokered private placement pursuant to the listed issuer financing exemption (the “Listed Issuer Financing Exemption”) under Part 5A of National Instrument 45-106 – Prospectus Exemptions (“NI 45-106”) (the “LIFE Offering”).

Key Points: 
  • The total LIFE Offering was comprised of the issuance of an aggregate of 34,905,498 Units at a price per Unit of C$0.07 for aggregate gross proceeds of $2,443,384.94.
  • For avoidance of doubt, the Company shall not be obligated to exercise the Acceleration Right at any time.
  • Due to additional interest, the Company is also pleased to announce a new non-brokered private placement offering of Units (the "Non-LIFE Offering").
  • To download the Fobi Investor Experience Wallet Pass to get enhanced access to investor information about Fobi, please visit our Investor Experience page .

***February 28, 2024 - Redistribution of prior news release dated February 2, 2024 for wide dissemination*** Fobi AI Announces Private Placement of Units for Aggregate Gross Proceeds of Up To C$2,000,000

Retrieved on: 
Wednesday, February 28, 2024
TSX Venture Exchange, AI, Marketing, News, Part, Sale, Exercise, Indian stock exchange, Unit, National instrument, Acceleration, Offering, Security (finance)

Each Unit shall consist of one (1) common share in the capital of the Company (a “Common Share”) and one (1) common share purchase warrant (each, a “Warrant”).

Key Points: 
  • Each Unit shall consist of one (1) common share in the capital of the Company (a “Common Share”) and one (1) common share purchase warrant (each, a “Warrant”).
  • For avoidance of doubt, the Company shall not be obligated to exercise the Acceleration Right at any time.
  • There is an offering document related to the Offering that can be accessed under the Company’s profile at www.sedarplus.ca and on the Company’s investor website at https://investors.fobi.ai/life-offering-subscription-agreement .
  • To download the Fobi Investor Experience Wallet Pass to get enhanced access to investor information about Fobi, please visit our Investor Experience page .

Taboola Reports Strong Q4 Net Income and Adj. EBITDA; Profits Beat High End of Guidance for Q4 and FY 2023; 2024 Guidance Calls for Record Year With Substantial Growth Across All Key Metrics

Retrieved on: 
Wednesday, February 28, 2024
Yahoo!, Share repurchase, Investment, Free cash flow, Part, Exercise, Appendix, GAAP, Webcast, Intellectual property, Privacy, Security (finance), Taboola, Risk, Bookkeeping

Certain elements of net income (loss), including share-based compensation expenses and warrant valuations, are not predictable due to the high variability and difficulty of making accurate forecasts.

Key Points: 
  • Certain elements of net income (loss), including share-based compensation expenses and warrant valuations, are not predictable due to the high variability and difficulty of making accurate forecasts.
  • As a result, it is impractical for us to provide guidance on net income (loss) or to reconcile our Adjusted EBITDA and Non-GAAP Net Income (Loss) guidance without unreasonable efforts.
  • Taboola's senior management team will discuss the Company's earnings on a call that will take place on February 28, 2024, at 8:30 AM ET.
  • You should not place undue reliance on these forward-looking statements, which speak only as of the date they were made.

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024
FAP, Senior, Research, FPI, Chemistry, Neuroscience, AXIN1, Part, Death, LLM, Software as a service, Hemangioma, Genetics, Cancer, Software, Letter, Business operations, Data, Matchmaker, APC, Machine learning, Real space, Biology, Development, Partnership, Therapy, Enamine, CCM, Myrexis, Library, Drug discovery, Safety, Biomarker, Clinical trial, IND, Clostridioides difficile infection, Roche, NF2, Biotechnology, Neurofibromatosis type II, Trial of the century, LILAC, Disease, Myriad Genetics, Administration, Pharmaceutical industry

SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2023.

Key Points: 
  • SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2023.
  • Research and Development Expenses: Research and development expenses were $69.5 million for the fourth quarter of 2023, compared to $44.0 million for the fourth quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $30.5 million for the fourth quarter of 2023 compared to $19.8 million for the fourth quarter of 2022.
  • Net Loss: Net loss was $93.0 million for the fourth quarter of 2023, compared to a net loss of $57.5 million for the fourth quarter of 2022.